NFX 179
Alternative Names: NFX-179Latest Information Update: 07 Jun 2024
At a glance
- Originator NFlection Therapeutics
- Class Antineoplastics; Chemopreventatives; Skin disorder therapies; Small molecules
- Mechanism of Action Mitogen-activated protein kinase kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Neurofibromatosis 1
- Preclinical Skin disorders; Squamous cell cancer
Most Recent Events
- 23 May 2024 NFlection Therapeutics withdraws prior to enrollment a phase II trial in Nevus because sponsor declined to proceed (NCT05195762)
- 13 Nov 2023 NFX 179 receives Orphan Drug status for Neurofibromatosis 1 in European Union, prior to November 2023
- 13 Nov 2023 Efficacy, pharmacokinetics and adverse events data from a phase IIb trial for Neurofibromatosis type 1 released by NFlection Therapeutics